BH-A vs TSLA

The Advanced Deterministic Scorecard reveals a weak fundamental health with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong revenue growth (10.3%) and solid balance sheet metrics (Current Ratio: 2.83, Debt/Equity: 0.60), the company's profitability is alarmingly thin (0.54% net margin, 0.35% ROE) and the P/E ratio of 227.28 is drastically elevated compared to sector averages. The stock trades at a massive premium to its Graham Number of $474.68, with a current price of $2,434.13, suggesting severe overvaluation. While insider sentiment is neutral and recent price momentum is strong, the lack of earnings growth visibility, inconsistent earnings surprises, and deteriorating ROE raise serious concerns about sustainability.

Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.